Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts. Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype. Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days. Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion.

[1]  Ewout J. N. Groen,et al.  Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology , 2021, Nature Genetics.

[2]  Ashley R. Jones,et al.  SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed , 2021, Brain communications.

[3]  Ashley R. Jones,et al.  A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex , 2021, Scientific Reports.

[4]  Yan Li,et al.  Caveolin-1, a novel player in cognitive decline , 2021, Neuroscience & Biobehavioral Reviews.

[5]  H. Patel,et al.  Subpial Gene Delivery of synapsin‐promoted Caveolin‐1 Prolongs Survival in hSODG93A mice Model of ALS , 2021, The FASEB Journal.

[6]  M. Snyder,et al.  Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis , 2020, Neuron.

[7]  Andrea D Matlock,et al.  Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines , 2020, Nature Neuroscience.

[8]  L. Van Den Bosch,et al.  C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD? , 2020, Acta Neuropathologica.

[9]  M. Igarashi,et al.  Neuronal Signaling Involved in Neuronal Polarization and Growth: Lipid Rafts and Phosphorylation , 2020, Frontiers in Molecular Neuroscience.

[10]  N. Wray,et al.  Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene , 2020, Cell reports.

[11]  N. Wray,et al.  ALS in Danish Registries , 2020, Neurology: Genetics.

[12]  F. Mastaglia,et al.  Structural Variants May Be a Source of Missing Heritability in sALS , 2020, Frontiers in Neuroscience.

[13]  O. Hardiman,et al.  Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. , 2019, JAMA neurology.

[14]  Xiao-fan Jiang,et al.  Neurons can upregulate Cav-1 to increase intake of endothelial cells-derived extracellular vesicles that attenuate apoptosis via miR-1290 , 2019, Cell Death & Disease.

[15]  S. Newhouse,et al.  C9orf72 intermediate expansions of 24–30 repeats are associated with ALS , 2019, Acta Neuropathologica Communications.

[16]  Alexander I. Young Solving the missing heritability problem , 2019, PLoS genetics.

[17]  H. Patel,et al.  Neuron‐targeted caveolin‐1 improves neuromuscular function and extends survival in SOD1G93A mice , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Timothy A. Miller,et al.  Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia , 2019, bioRxiv.

[19]  C. Mandyam,et al.  Neuron-Targeted Caveolin-1 Promotes Ultrastructural and Functional Hippocampal Synaptic Plasticity , 2018, Cerebral cortex.

[20]  E. Fraenkel,et al.  Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism , 2018, eLife.

[21]  J. Rowe,et al.  Genetic screening in sporadic ALS and FTD , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  Annelot M. Dekker,et al.  Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis , 2017, European Journal of Human Genetics.

[23]  C. Mandyam,et al.  Neuron‐specific caveolin‐1 overexpression improves motor function and preserves memory in mice subjected to brain trauma , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  A. Al-Chalabi,et al.  Gene discovery in amyotrophic lateral sclerosis: implications for clinical management , 2017, Nature Reviews Neurology.

[25]  C. Mandyam,et al.  Neuron-Targeted Caveolin-1 Improves Molecular Signaling, Plasticity, and Behavior Dependent on the Hippocampus in Adult and Aged Mice , 2017, Biological Psychiatry.

[26]  T. Hortobágyi,et al.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[27]  Zhi-rui Zhou,et al.  Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  A. Al-Chalabi,et al.  Amyotrophic lateral sclerosis: moving towards a new classification system , 2016, The Lancet Neurology.

[29]  Annelot M. Dekker,et al.  Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis , 2016, Nature Genetics.

[30]  J. Taipale,et al.  The role of enhancers in cancer , 2016, Nature Reviews Cancer.

[31]  Robert H. Brown,et al.  Endogenous retroviruses in ALS: A reawakening? , 2015, Science Translational Medicine.

[32]  Christian A. Ross,et al.  Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS , 2015, Nature Neuroscience.

[33]  B. Cupid,et al.  Establishing the UK DNA Bank for motor neuron disease (MND) , 2015, BMC Genetics.

[34]  P. Scacheri,et al.  Enhancer variants: evaluating functions in common disease , 2014, Genome Medicine.

[35]  A. Al-Chalabi,et al.  The epidemiology of ALS: a conspiracy of genes, environment and time , 2013, Nature Reviews Neurology.

[36]  P. Insel,et al.  Neuron-targeted Caveolin-1 Protein Enhances Signaling and Promotes Arborization of Primary Neurons* , 2011, The Journal of Biological Chemistry.

[37]  A. Miyanohara,et al.  Loss of Caveolin-1 Accelerates Neurodegeneration and Aging , 2010, PloS one.

[38]  A. Al-Chalabi,et al.  An estimate of amyotrophic lateral sclerosis heritability using twin data , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  Orla Hardiman,et al.  Cognitive impairment in amyotrophic lateral sclerosis , 2007, The Lancet Neurology.

[40]  B. Miller,et al.  Are amyotrophic lateral sclerosis patients cognitively normal? , 2003, Neurology.

[41]  E. Suchman,et al.  The American Soldier: Adjustment During Army Life. , 1949 .

[42]  E. Suchman,et al.  The American soldier: Adjustment during army life. (Studies in social psychology in World War II), Vol. 1 , 1949 .